MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells

<div>MMP9 and CCL1 downregulated DC-CIK cells markedly improved the immune function of the activated T cells. DC-CIK cells were transfected with MMP9 shRNAs, CCL1 shRNAs, or/and CCL1 plasmid and were cocultured with T cells. (a) The percentages of T-lymphocyte subsets (CD3+, CD3+CD4+, and CD3+CD8+) were certified by flow cytometry. (b) The number of the CD4+PD-1+ and CD8+PD-1+ cells was determined through flow cytometry. TNormal group means T cells isolated from normal human mononuclear cells.</div>

Stem Cells International

fig5

Figure 5

Figure 5: MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells 

Figure 5 | MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells 